Private company

Flexion Therapeutics

American biotechnology company

Flexion Therapeutics, Inc. is an American biopharmaceutical company based in Burlington, Massachusetts that is focused on the discovery, development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), the most common form of arthritis.³ From Wikipedia, CC BY-SA 4.0

Last updated Oct 18, 2026.

Overview

Jan 1, 2007Founded¹

Industrybiotechnology¹
HeadquartersWoburn¹
Websitewww.flexiontherapeutics.com
Legal formDelaware corporation¹
Incorporated inDE⁴
Business address10 Mall Road, Suite 301, Burlington, Ma 01803⁴
Filer categoryNon-accelerated filer, Smaller reporting company⁴

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2020

-108.7%Operating margin⁵

-132.9%Net margin⁵

17.3%Revenue growth, 2020⁵

-$80.6MFree cash flow⁵

Where the money goes

Where each dollar of revenue went, fiscal 2020

Research and developmentSelling, general and admin

Cost of revenue10¢$19.2M
Research and development27¢$54.3M
Selling, general and admin53¢$105.0M
Interest10¢$20.0M
Income tax0¢$495.0K

Out of $85.6M in revenue.⁵ The company lost money this year.

Financial statements

Revenue⁶⁵$85.6M in 2020+23999% since 2017

Operating income⁷⁸⁹⁶⁵-$93.0M in 2020+245% since 2014

Net income⁷⁸⁹⁶⁵-$113.7M in 2020+316% since 2014

Fiscal year	2014	2015	2016	2017	2018	2019	2020
Revenue				$355.0K⁶	$22.5M⁵	$73.0M⁵	$85.6M⁵
Cost of revenue				$4.0K⁶	$7.3M⁵	$10.0M⁵	$19.2M⁵
Research and development	$17.9M⁷	$32.7M⁸	$41.3M⁹	$51.2M⁶	$53.1M⁵	$69.6M⁵	$54.3M⁵
Selling, general and admin		$13.4M⁸	$28.5M⁹	$78.8M⁶	$121.3M⁵	$129.7M⁵	$105.0M⁵
Operating income	-$27.0M⁷	-$46.1M⁸	-$69.8M⁹	-$129.7M⁶	-$159.2M⁵	-$136.3M⁵	-$93.0M⁵
Interest	$401.4K⁷	$571.0K⁸	$1.7M⁹	$11.3M⁶	$15.7M⁵	$17.1M⁵	$20.0M⁵
Income tax	$0¹⁰	$0⁸	$0⁹	$0⁶	$0⁵	$0⁵	$495.0K⁵
Net income	-$27.3M⁷	-$46.3M⁸	-$71.9M⁹	-$137.5M⁶	-$169.7M⁵	-$149.8M⁵	-$113.7M⁵

Total assets¹⁰⁷⁸⁹⁶⁵$251.9M in 2020+64% since 2014

Total liabilities¹⁰⁷⁸⁹⁶⁵$268.6M in 2020+3095% since 2014

Shareholders’ equity⁸⁹⁶⁵-$16.7M in 2020

Cash⁸⁹⁶⁵$107.7M in 2020+4% since 2014

Long-term debt¹⁰⁷⁸⁹⁶⁵$44.1M in 2020+2690% since 2014

Fiscal year	2014	2015	2016	2017	2018	2019	2020
Cash	$103.1M⁸	$62.9M⁸	$30.9M⁸	$127.8M⁹	$87.2M⁶	$82.3M⁵	$107.7M⁵
Current assets	$152.1M¹⁰	$112.1M⁷	$209.4M⁸	$398.0M⁹	$285.0M⁶	$195.7M⁵	$225.8M⁵
Total assets	$153.3M¹⁰	$127.1M⁷	$226.3M⁸	$441.3M⁹	$295.8M⁶	$217.6M⁵	$251.9M⁵
Current liabilities	$6.8M¹⁰	$8.1M⁷	$17.5M⁸	$30.6M⁹	$36.6M⁶	$36.2M⁵	$55.3M⁵
Long-term debt	$1.6M¹⁰	$15.0M⁷	$21.4M⁸	$12.9M⁹	$3.6M⁶	$40.2M⁵	$44.1M⁵
Total liabilities	$8.4M¹⁰	$23.2M⁷	$39.2M⁸	$181.0M⁹	$185.7M⁶	$237.7M⁵	$268.6M⁵
Shareholders’ equity	$144.9M⁸	$104.0M⁹	$187.0M⁶	$260.3M⁵	$110.1M⁵	-$20.1M⁵	-$16.7M⁵
Shares outstanding	21.4M shares¹⁰	21.6M shares⁷	31.7M shares⁸	37.6M shares⁹	37.9M shares⁶	38.4M shares⁵	49.4M shares⁵

Cash from operations⁹⁶⁵-$70.6M in 2020+13% since 2016

Capital spending⁷⁸⁹⁶⁵$10.1M in 2020+1155% since 2014

Free cash flow⁹⁶⁵-$80.6M in 2020+14% since 2016

Fiscal year	2014	2015	2016	2017	2018	2019	2020
Cash from operations			-$62.5M⁹	-$107.8M⁶	-$160.4M⁵	-$148.8M⁵	-$70.6M⁵
Capital spending	$802.5K⁷	$5.2M⁸	$8.4M⁹	$2.1M⁶	$852.0K⁵	$3.9M⁵	$10.1M⁵
Free cash flow			-$70.9M	-$110.0M	-$161.3M	-$152.7M	-$80.6M

Compare Flexion Therapeutics with another company

Leadership

Who has led Flexion Therapeutics, and when. Pick a name to see everywhere that person has worked.

Chief executive

Michael D. Clayman2014–2021

President

Michael D. Clayman2014–2021

Chief financial officer

2010201520202025

Chief executive officerMichael D. Clayman Feb 11, 2014 to Nov 19, 2021¹¹
PresidentMichael D. Clayman Feb 11, 2014 to Nov 19, 2021¹¹
Chief financial officerDavid Arkowitz May 7, 2018 to May 12, 2021¹²
Chief financial officerFrederick W. Driscoll Feb 11, 2014 to Nov 19, 2021¹³

Board members and other officers (30)

Chief Business OfficerAdam Muzikant Jan 6, 2021 to Nov 19, 2021¹⁴
Chief Commercial OfficerMelissa Layman Mar 13, 2020 to Nov 19, 2021¹⁵
Chief Strategy OfficerChristina Willwerth Jan 22, 2019 to Nov 19, 2021¹⁶
Chief Medical OfficerYamo Deniz Apr 5, 2017 to Sep 15, 2017¹⁷
Chief Medical OfficerScott Kelley Dec 15, 2017 to Mar 15, 2021¹⁸
Chief Regulatory OfficerKerry Wentworth Dec 29, 2017 to Nov 19, 2021¹⁹
Chief Business OfficerArthur Fratamico Feb 11, 2014 to Feb 11, 2014²⁰
Chief Medical OfficerNeil Bodick Feb 11, 2014 to Jan 7, 2020²¹
Board memberUtpal Koppikar Jul 12, 2021 to Nov 19, 2021²²
Board memberElizabeth Kwo Aug 20, 2020 to Nov 19, 2021²³
Board memberMark Stejbach Sep 14, 2016 to Nov 19, 2021²⁴
Board memberScott A. Canute Mar 6, 2015 to Nov 19, 2021²⁵
Board memberAlan Milinazzo Feb 11, 2014 to Nov 19, 2021²⁶
Board memberAndrew J. Schwab Feb 11, 2014 to Mar 4, 2014²⁷
Board memberBradley J. Bolzon Phd. Feb 11, 2014 to Sep 12, 2014²⁸
Board memberElaine Jones V. Feb 11, 2014 to Feb 11, 2014²⁹
Board memberHeath Lukatch Feb 11, 2014 to Nov 19, 2021³⁰
Board memberMichael D. Clayman Feb 11, 2014 to Nov 19, 2021¹¹
Board memberPatrick J. Mahaffy Feb 11, 2014 to Nov 19, 2021³¹
Board memberRafael Tordjman Feb 11, 2014 to Mar 4, 2014³²
Board memberSamuel D. Colella Feb 11, 2014 to Nov 19, 2021³³
Board memberC. Ann Merrifield Jun 13, 2014 to Nov 19, 2021³⁴
Board memberSandesh Mahatme Jul 24, 2014 to Jun 12, 2020³⁵
Board memberBarbara N. Lubash Sep 12, 2014 to Sep 12, 2014³⁶
Board memberBrian G. Atwood Sep 12, 2014 to Sep 12, 2014³⁶
Board memberCharles M. Warden Sep 12, 2014 to Sep 12, 2014³⁷
Board memberDonald B. Milder Sep 12, 2014 to Sep 12, 2014³⁶
Board memberRebecca B. Robertson Sep 12, 2014 to Sep 12, 2014³⁶
Board memberRoss A. Jaffe Md. Sep 12, 2014 to Sep 12, 2014³⁶
Board memberWilliam J. Link Phd. Sep 12, 2014 to Sep 12, 2014³⁶

Timeline

Feb 11, 2014New chief executive Michael D. Clayman becomes CEO¹¹
Jan 1, 2007Founded Founded¹

Filings

43 filings to the SEC since October 2021: 1 quarterly reports, 2 major events, 19 insider forms, 2 large holders, 19 other. The latest 20:

The 43 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last three years, summarized. The full record is on SEC EDGAR.

Insider trades and holders

Large holders

Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 2 such filings since October 2021:

Nov 24, 2021SC 13G
Nov 9, 2021SC 13G/A

From Forms 4 and Schedules 13D and 13G filed with the SEC.

Sources

The numbers on this page point here. Each one links to the record it came from.

1
WikidataFlexion Therapeutics on Wikidata
2
SEC EDGARFlexion Therapeutics filings on SEC EDGAR
3
WikipediaFlexion Therapeutics on Wikipedia
4
SEC EDGARFlexion Therapeutics filings on SEC EDGAR
5
SEC EDGARFlexion Therapeutics 10-K for fiscal 2020
6
SEC EDGARFlexion Therapeutics 10-K for fiscal 2017
7
SEC EDGARFlexion Therapeutics 10-K for fiscal 2014
8
SEC EDGARFlexion Therapeutics 10-K for fiscal 2015
9
SEC EDGARFlexion Therapeutics 10-K for fiscal 2016
10
SEC EDGARFlexion Therapeutics 10-K for fiscal 2014
11
SEC EDGARMichael D. Clayman, Chief executive officer
12
SEC EDGARDavid Arkowitz, Chief financial officer
13
SEC EDGARFrederick W. Driscoll, Chief financial officer
14
SEC EDGARAdam Muzikant, Chief Business Officer
15
SEC EDGARMelissa Layman, Chief Commercial Officer
16
SEC EDGARChristina Willwerth, Chief Strategy Officer
17
SEC EDGARYamo Deniz, Chief Medical Officer
18
SEC EDGARScott Kelley, Chief Medical Officer
19
SEC EDGARKerry Wentworth, Chief Regulatory Officer
20
SEC EDGARArthur Fratamico, Chief Business Officer
21
SEC EDGARNeil Bodick, Chief Medical Officer
22
SEC EDGARUtpal Koppikar, Board member
23
SEC EDGARElizabeth Kwo, Board member
24
SEC EDGARMark Stejbach, Board member
25
SEC EDGARScott A. Canute, Board member
26
SEC EDGARAlan Milinazzo, Board member
27
SEC EDGARAndrew J. Schwab, Board member
28
SEC EDGARBradley J. Bolzon Phd., Board member
29
SEC EDGARElaine Jones V., Board member
30
SEC EDGARHeath Lukatch, Board member
31
SEC EDGARPatrick J. Mahaffy, Board member
32
SEC EDGARRafael Tordjman, Board member
33
SEC EDGARSamuel D. Colella, Board member
34
SEC EDGARC. Ann Merrifield, Board member
35
SEC EDGARSandesh Mahatme, Board member
36
SEC EDGARBarbara N. Lubash, Board member
37
SEC EDGARCharles M. Warden, Board member